SEC EDGAR · Financial report
PCVX: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
Follow PCVX- Became public
- Nov 4, 2026, 4:18 PM EST
- Event / period date
- Sep 30, 2026
- Collected
- Nov 7, 2026, 6:36 PM EST
Why this is connected
This filing identifies Vaxcyte, Inc. as the issuer of the security. The company's SEC identifier connects it to PCVX.
Source evidence
Read the source excerpt or record
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 3, 2026, the Company entered into an amendment to the Executive Change in Control and Severance Agreement between the Company and Mikhail Eydelman, its Senior Vice President, General Counsel (as so amended, the “Amended Agreement”). In connection with certain organizational changes implemented as of August 31, 2026 impacting Mr. Eydelman’s role, Mr. Eydelman and the Company have formally agreed that he will remain employed until at least the earlier of (i) May 31, 2027 (the “Scheduled Date”), or (ii) the date on which an Early Termination Event occurs (the period between August 31, 2026 and the earlier to occur of the Scheduled Date or Early Termination Event, the “Continued Employment Period”). During the Continued Employment Period, Mr. Eydelman will continue to vest in his Company equity awards and to earn base salary and annual incentives as currently in effect. The Amended Agreement also preserves Mr. Eydelman’s Good Reason severance rights for the duration of the Continued Employment Period. Unless Mr. Eydelman’s employment continues past the Scheduled Date, upon his termination of employment for Good Reason, Mr. Eydelman will be entitled to receive the severance benefits that apply upon a termination of his employment for Good Reason under the Change in Control and Severance Agreement as previously disclosed, except that, pursuant to the Amended Agreement, the severance benefits to apply to Mr. Eydelman upon a Qualifying Termination are modified such that the references to 12 months have been reduced to 9 months. Capitalized terms not otherwise defined herein have the meanings set forth in the Ame
Congressional trading in PCVX
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Sep 4, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Jul 16, 2026 · disclosed Sep 4, 2026 · filed 50 days later
- Jun 8, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded May 13, 2026 · disclosed Jun 8, 2026
- Jun 8, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded May 12, 2026 · disclosed Jun 8, 2026
- May 6, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Apr 28, 2025 · disclosed May 6, 2025
- May 6, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Apr 15, 2025 · disclosed May 6, 2025
- May 6, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Apr 14, 2025 · disclosed May 6, 2025
- Apr 11, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded Mar 5, 2025 · disclosed Apr 11, 2025
- Jan 20, 2023$1K–$15K
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.